Infectious Diseases News and Research

RSS

Low-income groups slow to seek treatment for stroke

People with lower incomes are less likely to present at a hospital within 3 hours of stroke symptoms and thus have lower rates of thrombolysis therapy or post-stroke care than their more affluent counterparts, according to a retrospective analysis.

22 Jan 2013

Simulation ticks box for checklists in surgical care

The management of operating-room crises could be significantly improved by using checklists, say researchers in the New England Journal of Medicine.

22 Jan 2013

Routine gastric volume monitoring thrown out

Monitoring gastric residual volumes in critically ill patients receiving enteral nutrition does not prevent them from developing ventilator-associated pneumonia, shows a randomized trial.

22 Jan 2013

PathCentral announces roll-out of new pathology network

PathCentral, a technology-enabled company dedicated to the success of the international pathology community, and China-based Kindstar Globalgene Technology, Inc., today announced the roll-out of the PathCentral Pathology Network, an online professional pathology network that will enable Kindstar to access US pathologists and facilitate pathology consultations for more than 3,300 hospitals throughout China.

22 Jan 2013

Simcere enters share transfer agreement with Devont Asset Management

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the Company entered into a share transfer agreement with Devont Asset Management Limited on January 15th 2013 to sell an approximately 35% equity interest in Shanghai Celgen Bio-Pharmaceutical Co., Ltd. for a cash consideration of RMB 302 million.

22 Jan 2013

Studies suggest a new approach to treating HIV

A team of researchers based at Johns Hopkins has decoded a system that makes certain types of immune cells impervious to HIV infection.

22 Jan 2013

Scientists identify new mechanism that turns CD4 helper T lymphocytes into killer cells

A research team led by the La Jolla Institute for Allergy & Immunology has discovered the mechanism that enables CD4 helper T cells to assume the more aggressive role of killer T cells in mounting an immune attack against viruses, cancerous tumors and other damaged or infected cells.

21 Jan 2013

G-CON completes delivery and installation of POD system in PaxVax's GMP production facility

G-CON today announced the completed delivery and installation of the ground-breaking POD system in PaxVax's licensed GMP production facility based in San Diego, California where PaxVax manufactures innovative and socially responsible oral vaccines against infectious diseases.

19 Jan 2013

Leprosy bacteria able to change the make-up of Schwann cells

A discovery about the way in which bugs spread throughout the body could help to develop stem cell treatments.

19 Jan 2013

ECLS system supports flu patients in their recovery from severe respiratory problems

In recent weeks the intensive critical care units at University Health Network's Toronto General Hospital have used Extra Corporeal Lung Support (ECLS) to support five influenza (flu) patients in their recovery from severe respiratory problems.

19 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject.

18 Jan 2013

Early life exposure to gut microbes protects against autoimmune disease

Early life exposure to normal bacteria of the GI tract (gut microbes) protects against autoimmune disease in mice, according to research published on-line in the January 17 edition of Science. The study may also have uncovered reasons why females are at greater risk of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and lupus compared to males.

18 Jan 2013

Life Technologies, ASU partner on new project to quickly measure radiation exposure

Arizona State University's Biodesign Institute- has announced a partnership with Life Technologies Corporation as it enters the next phase of a multi-million-dollar, multi-institutional research project to develop a medical device to rapidly assess an individual's exposure to radiation in the event of a nuclear incident.

18 Jan 2013